News | News By Subject | News by Disease News By Date | Search News

Fabry's disease News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Groundbreaking: Amicus (FOLD) Surges as the FDA Changes Its Tune on Fabry Disease Drug     7/11/2017
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug     8/21/2014
Amicus Therapeutics, Inc. (FOLD) Shoots Up As Lead Drug Migalastat Is Effective In Phase 3 Trial; Stock Up +20.65% At Market Close (April 29, 2014)     4/30/2014
Amicus Therapeutics, Inc. (FOLD) Shelves New-Drug Filing for Fabry Disease Drug     6/19/2013
Amicus Therapeutics, Inc. (FOLD), GlaxoSmithKline (GSK) Say Treatment Misses Goal     12/20/2012
GlaxoSmithKline (GSK) Invests $18.6 Million in Amicus Therapeutics, Inc. (FOLD) to Expand Fabry Disease Drug Deal     7/18/2012
Amicus Therapeutics, Inc. (FOLD) Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease     1/6/2012
Shire plc Seeks Fast-Track Approval for Fabry Disease Drug     10/31/2011
Protalix Biotherapeutics, Inc. (PLX) Plans Human Clinical Tests of Medication for Rare Fabry's Disease     3/24/2011
Shire plc Provides Update on BLA Filing for REPLAGAL(R) with the Shire Pharmaceuticals (SHPGY); Receives Fast Track Designation     2/24/2010
Phase I Clinical Studies Demonstrate Safety And Initial "Proof Of Concept" Amicus Therapeutics, Inc.'s Fabry Disease Drug     9/8/2005
Transkaryotic Therapies, Inc. (TKT) (TKTX) To End Efforts To Seek U.S. Approval Of Replagal     1/13/2004

News from Around the Web

Press Releases
Amicus (FOLD) Announces Approval For Galafold (Migalastat) For Treatment Of Fabry Disease In Australia     8/16/2017
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease     5/9/2017
Amicus (FOLD) Launches Galafold (Migalastat) For Treatment Of Fabry Disease In France     5/2/2017
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease     8/10/2016
Protalix Biotherapeutics, Inc. (PLX) Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual Worldsymposium 2016     3/3/2016
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA     11/16/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Long Term Data On PRX-102 For Fabry Disease     10/19/2015
Amicus (FOLD) Not Likely To Submit NDA For Migalastat Monotherapy This Year     10/2/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I/II Interim Clinical Data On The 1mg/Kg Cohort Of PRX-102 For Fabry Disease     9/9/2015
Amicus Therapeutics, Inc. (FOLD)' Fabry Monotherapy Granted Accelerated Assessment By European Regulators     5/26/2015
Genzyme (GENZ) Initiates Phase 2a Clinical Trial To Evaluate Oral Therapy For Fabry Disease     4/21/2015
Amicus Therapeutics, Inc. (FOLD) Provides Positive Global Regulatory Updates From European Medicines Agency And FDA Meetings For Fabry Monotherapy     3/19/2015
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015     2/10/2015
Protalix Biotherapeutics, Inc. (PLX) Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease     2/2/2015
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study     1/8/2015